Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children: German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP);Empfehlungen zur Therapie, Chemoprävention und Chemoprophylaxe der Tuberkulose im Erwachsenen- und Kindesalter: Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (DZK), Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (DGP)

Pneumologie

Volumn 66, Issue 3, 2012, Pages 133-171

  Schaberg, T ^a,b   Bauer, T ^b,c   Castell, S ^b   Dalhoff, K ^d   Detjen, A ^e   Diel, R ^b   Greinert, U ^f   Hauer, B ^g   Lange, C ^f   Magdorf, K ^h   Loddenkemper, R ^b  

^a Zentrum fur Pneumologie   (Germany)

^b Deutsches Zentralkomitee Zur Bekämpfung der Tuberkulose E â Scaron V DZK   (Germany)

^c HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^f RESEARCH CENTER BORSTEL   (Germany)

^g ROBERT KOCH INSTITUTE   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; CIPROFLOXACIN; ETHAMBUTOL; OFLOXACIN; PYRAZINAMIDE;

ADULT DISEASE; ANTIBIOTIC RESISTANCE; ARTICLE; BLADDER CANCER; CHEMOPROPHYLAXIS; CHILDHOOD DISEASE; EXTRAPULMONARY TUBERCULOSIS; GERMANY; HEALTH CARE ORGANIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LATENT TUBERCULOSIS; LIVER FAILURE; MEDICAL SOCIETY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADULT; ANTITUBERCULAR AGENTS; CHILD; GERMANY; HUMANS; PULMONARY MEDICINE; RECURRENCE; TUBERCULOSIS;

EID: 84857918386     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0031-1291619     Document Type: Article

References (185)

1. Robert Koch-Institut Eckdaten zur Tuberkulose in Deutschland für das Jahr 2009. Epidemiol Bull: 2011; 11 83 85
2. Robert Koch Institut Bericht zur Epidemiologie der Tuberkulose in Deutschland 2009. 2011; www.rki.de
3. Schaberg T, Forssbohm M, Hauer B et al. Richtlinien zur medikamentösen Behandlung der Tuberkulose im Erwachsenen- und Kindesalter. Pneumologie: 2001; 55 494 511 (Pubitemid 33141021)
4. World Health Organization Treatment of tuberculosis guidelines. 4th volume. WHO/HTM/TB 2009. 420 ed. 2009
5. World Health Organization Guidelines for the programmatic management of drug-resistent tuberculosis. 2008; 402 ed. WHO/HTM/TB/2008
6. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. 2011; 6. ed. WHO/HTM/TB/2011
7. Blumberg HM, Burman WJ, Chaisson RE et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med: 2003; 167 603 662
8. National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at NICE NICE clinical guideline 117. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011
9. Ait-Khaled N, Alarcn E, Armengol R et al. Management of Tuberculosis. International Union Against Tuberculosis and Lung Diseases: 2010
10. Bartmann K, Radenbach KL, Zierski M. Wandlungen in den Auffassungen und der Durchführung der antituberkulösen Chemotherapie. Prax Klin Pneumol: 1985; 39 397 420 (Pubitemid 16198381)
11. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis: 1999; 3 (suppl 2) 231 279
12. Radenbach D, Nowak D, Magnussen H. Die Chemotherapie der Lungentuberkulose - Prinzipien, Therapiestudien, Konsequenzen für die Praxis. Prax Klin Pneumol: 1988; 42 778 786 (Pubitemid 19005279)
13. Yew WW, Lange C, Leung CC. Treatment of tuberculosis update 2010. Eur Respir J: 2010; 37 441 462
14. Mitchison DA. Basic mechanisms of chemotherapy. Chest: 1980; 76 771 781
15. Mitchison DA. The action of antituberculosis drugs during short-course chemotherapy. Tubercle: 1985; 66 219 225 (Pubitemid 16150082)
16. Bartmann K. Antituberculosis drugs. Berlin, Heidelberg, New York Springer: 1988
17. Jindani A, Aber VR, Edwards EA et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis: 1980; 121 939 941
18. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med: 2003; 167 1348 1354 (Pubitemid 36609718)
19. Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis: 1981; 123 367 371 (Pubitemid 11105700)
20. Mitchison DA. Pyrazinamide in the chemoprophylaxis of tuberculosis. Am Rev Respir Dis: 1990; 142 1467
21. Cole ST, Telenti A. Drug resistance in Mycobacterium tuberculosis. Eur Respir J Suppl: 1995; 20 701 713
22. McClatchy JH. Antimycobacterial drugs: mechanism of action, drug resistance, susceptibility testing and assays of activity in bacteriologic fluids. In: Lorian V. editor. Antibiotics in laboratory medicine. Baltimore Williams and Wilkens: 1986; 161 227
23. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis: 1998; 2 10 15 (Pubitemid 28108937)
24. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev: 1995; 8 496 514
25. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol: 1970; 20 810 814
26. Vareldzis B, Grosset J, de Kantor J et al. Drug-resistant tuberculosis: laboratory issues. Tuber Lung Dis: 1994; 75 1 4
27. Sirgel FA, Botha FJJ, Parkin DP et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother: 1993; 32 867 875 (Pubitemid 24026587)
28. Crofton J. Drug treatment of tuberculosis. Standard chemotherapy. Br Med J: 1960; 2 370 373
29. Snider DE, Graczyk J, Bek E et al. Supervised six-month treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis: 1984; 130 1091 1094 (Pubitemid 15186171)
30. Singapore Tuberculosis Service Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle: 1981; 62 95 102
31. East and Central African and British Medical Research Council Clinical controlled trial of four short-course regimens of chemotherapy (three six-month, and one eight month) for pulmonary tuberculosis. Tubercle: 1983; 64 153 166
32. Second East Africa BMRC Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis: 1976; 114 471 475
33. British Thoracic Society A controlled trial of 6-month chemotherapy in pulmonary tuberculosis. First report: results during treatment. Br J Dis Chest: 1981; 75 141 153
34. British Thoracic Society A controlled trial of 6-month chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. Br J Dis Chest: 1984; 78 330 336
35. Singapore Tuberculosis Service Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis: 1986; 133 779 783
36. Singapore Tuberculosis Service Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis: 1991; 143 707 712
37. Singapore Tuberculosis Service and British Medical Research Council Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis: 1985; 132 374 388
38. Singapore Tuberculosis Service and British Medical Research Council Five-year follow-up of a clinical trial of three 6-month regimens of chemotheray given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis: 1988; 137 1147 1150
39. Hong Kong Chest Service Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 month for pulmonary tuberculosis. Second report: the results up to 24 month. Tubercle: 1982; 63 89 98
40. Hong Kong Chest Service Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis: 1987; 136 1339 1342
41. Hong Kong Chest Service Controlled trial of 2, 4, and 6 month of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Am Rev Respir Dis: 1991; 143 700 706
42. Hong Kong Chest Service A controlled clinical comparison of 6 and 8 month of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis: 1991; 143 262 267
43. Hong Kong Chest Service A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuber Lung Dis: 1992; 73 59 67
44. Hong Kong Chest Service/Tuberculosis Research Centre A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Am Rev Respir Dis: 1989; 139 871 876
45. Lin MY, Lin SJ, Chan LC et al. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis: 2010; 14 806 818
46. Peloquin CA, Namdar R, Dodge AA et al. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis: 1999; 3 703 710 (Pubitemid 29378471)
47. Peloquin CA, Bulpitt AE, Jaresko GS et al. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother: 1999; 43 568 572 (Pubitemid 29109520)
48. Peloquin CA, Namdar R, Singleton MD et al. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest: 1999; 115 12 18 (Pubitemid 29047048)
49. Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med: 2010; 363 1005 1015
50. Hillemann D, Rüsch-Gerdes S, Boehme C et al. Rapid molecular detection of extrapulmonary tuberculosis by automated GeneXpert(R) MTB/RIF system. J Clin Microbiol: 2011; 49 1202 1205
51. Richter E, Rüsch-Gerdes S, Hillemann D. Drug-susceptibility testing in TB: current status and future prospects. Expert Rev Respir Med: 2009; 3 497 510
52. Chiang CY, Schaaf HS. Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis: 2010; 14 672 682
53. Forßbohm M, Loytved G, Königstein B. Handbuch Tuberkulose für Fachkräfte an Gesundheitsämtern. Düsseldorf: 2009
54. Arbeitskreis Tuberkulose im BVGD Sicherung des Behandlungserfolges bei Tuberkulose. Entwurf einer Empfehlung für Deutschland. In: 33. Informationsbericht des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose (DZK). Berlin: 2010
55. National Collaborating Centre for Chronic Conditions Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London Royal College of Physicians: 2006
56. Lienhardt C, Cook SV, Burgos M et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. Jama: 2011; 305 1415 1423
57. Ferrer J. Pleural tuberculosis. Eur Respir J: 1997; 10 942 947 (Pubitemid 27180212)
58. Wyser C, Walzl G, Smedema JP et al. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Chest: 1996; 110 333 338 (Pubitemid 26269256)
59. Campbell IA, Dyson AJ. Lymph node tuberculosis: a comparison of various methods of treatment. Tubercle: 1977; 58 171 179 (Pubitemid 8247013)
60. Sellar RS, Corbett EL, D'Sa S et al. Treatment for lymph node tuberculosis. BMJ: 2010; 340 63
61. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med: 2007; 175 367 416
62. Cek M, Lenk S, Naber KG et al. EAU guidelines for the management of genitourinary tuberculosis. Eur Urol: 2005; 48 353 362 (Pubitemid 41188388)
63. Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am: 1992; 19 565 572
64. Klimach OE, Ormerod LP. Gastrointestinal tuberculosis: a retrospective review of 109 cases in a district general hospital. Q J Med: 1985; 56 569 578 (Pubitemid 16222505)
65. Sherman S, Rohwedder JJ, Ravikrishnan KP et al. Tuberculous enteritis and peritonitis. Report of 36 general hospital cases. Arch Intern Med: 1980; 140 506 508 (Pubitemid 10156653)
66. Tan KK, Chen K, Sim R. The spectrum of abdominal tuberculosis in a developed country: a single institution's experience over 7 years. J Gastrointest Surg: 2009; 13 142 147
67. Almadi MA, Ghosh S, Aljebreen AM. Differentiating intestinal tuberculosis from Crohn's disease: a diagnostic challenge. Am J Gastroenterol: 2009; 104 1003 1012
68. Serke M, Hauer B, Loddenkemper R. Chemotherapy of osteoarticular tuberculosis. Orthopaede: 1999; 28 375 380
69. Evans DJ. The use of adjunctive corticosteroids in the treatment of pericardial, pleural and meningeal tuberculosis: do they improve outcome? Respir Med: 2008; 102 793 800
70. Ntsekhe M, Wiysonge C, Volmink JA et al. Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven. QJM: 2003; 96 593 599 (Pubitemid 36987259)
71. Syed FF, Mayosi BM. A modern approach to tuberculous pericarditis. Prog Cardiovasc Dis: 2007; 50 218 236 (Pubitemid 47633679)
72. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb): 2010; 90 279 292
73. Donald PR. The chemotherapy of tuberculous meningitis in children and adults. Tuberculosis (Edinb): 2010; 90 375 392
74. Thwaites G, Fisher M, Hemingway C et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect: 2009; 59 167 187
75. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev: 2008; 01 CD002244
76. Alzeer AH, Fitz-Gerald JM. Corticosteroids and tuberculosis: risks and use as adjunct therapy. Tuber Lung Dis: 1993; 74 6 11 (Pubitemid 23080927)
77. Muthuswamy P, Hu TC, Carasso B et al. Prednisone as adjunctive therapy in the management of pulmonary tuberculosis. Chest: 1995; 107 1621 1630
78. Caminero JA, Sotgiu G, Zumla A et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis: 2010; 10 621 629
79. Velayati AA, Masjedi MR, Farnia P et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest: 2009; 136 420 425
80. Schaberg T, Gloger G, Reichert B et al. Drug-resistant pulmonary tuberculosis in Berlin, Germany 1987-1993. Eur Respir J: 1995; 8 278 284
81. Boehme CC, Nicol MP, Nabeta P et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet: 2011; 377 1495 1505
82. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol: 2007; 45 2635 2640 (Pubitemid 47295497)
83. Huang WL, Chi TL, Wu MH et al. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol: 2011; 49 2502 2508
84. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol: 2009; 47 1767 1772
85. Devasia RA, Blackman A, Gebretsadik T et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med: 2009; 180 365 370
86. Falzon D, Jaramillo E, Schunemann HJ et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J: 2011; 38 516 528
87. Uzun M, Erturan Z, Ang O. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis: 2002; 6 164 165 (Pubitemid 34263709)
88. Senol G, Erbaycu A, Ozsoz A. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey. J Chemother: 2005; 17 380 384 (Pubitemid 41284775)
89. Kim DH, Kim HJ, Park SK et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med: 2008; 178 1075 1082
90. Kwon JS, Kim YH, Suh GY et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis: 2008; 47 496 502
91. Eker B, Ortmann J, Migliori GB et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis: 2008; 14 1700 1706
92. Bloss E, Kuksa L, Holtz TH et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis: 2010; 14 275 281
93. Franke MF, Appleton SC, Bayona J et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis: 2008; 46 1844 1851
94. Cox HS, Kalon S, Allamuratova S et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One: 2007; 2 e1126
95. Nathanson E, Gupta R, Huamani P et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis: 2004; 8 1382 1384 (Pubitemid 39611587)
96. Van Deun A, Maug AK, Salim MA et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med: 2010; 182 684 692
97. Somocurcio JG, Sotomayor A, Shin S et al. Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax: 2007; 62 416 421 (Pubitemid 46698391)
98. Ormerod LP. Role of surgery in pulmonary multidrug-resistant tuberculosis. Thorax: 2007; 62 377 (Pubitemid 46698380)
99. Magdorf K, Bialek R, Detjen AK et al. Tuberkulose und nicht tuberkulöse mykobakterielle Krankheiten. In: DGPI Handbuch Infektionen bei Kindern und Jugendlichen. 5. Auflage. Stuttgart Thieme: 2009; 528 544
100. Marais BJ, Gie RP, Schaaf HS et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis: 2004; 8 392 402 (Pubitemid 38624845)
101. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis: 1999; 3 847 850 (Pubitemid 29488035)
102. Mack U, Migliori GB, Sester M et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J: 2009; 33 956 973
103. Marais BJ. Tuberculosis in children. Pediatr Pulmonol: 2008; 43 322 329 (Pubitemid 351544040)
104. Spyridis NP, Spyridis PG, Gelesme A et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis: 2007; 45 715 722 (Pubitemid 47378885)
105. Leung CC, Rieder HL, Lange C et al. Treatment of latent infection with M. tuberculosis: update 2010. Eur Respir J: 2010; 37 690 711
106. Diel R, Loytved G, Nienhaus A et al. New recommendations for contact tracing in tuberculosis. German Central Committee against Tuberculosis. Pneumologie: 2011; 65 359 378
107. World Health Organization Rapid Advice: Treatment of tuberculosis in children. 2010
108. Thee S, Detjen A, Quarcoo D et al. Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children. Int J Tuberc Lung Dis: 2007; 11 965 971 (Pubitemid 47425022)
109. Thee S, Detjen A, Wahn U et al. Pyrazinamide serum levels in childhood tuberculosis. Int J Tuberc Lung Dis: 2008; 12 1099 1101
110. Thee S, Detjen A, Wahn U et al. Rifampicin serum levels in childhood tuberculosis. Int J Tuberc Lung Dis: 2009; 13 1106 1111
111. Thee S, Detjen A, Wahn U et al. Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis. Scand J Infect Dis: 2010; 42 294 298
112. McMaster P, Isaacs D. Critical review of evidence for short course therapy for tuberculous adenitis in children. Pediatr Infect Dis J: 2000; 19 401 404 (Pubitemid 30307988)
113. Detjen AK, Magdorf K. Characteristics of childhood tuberculosis. Pneumologie: 2009; 63 207 218
114. Donald PR, Seifart HI. Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis. J Pediatr: 1989; 115 483 486 (Pubitemid 19223196)
115. Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am Rev Respir Dis: 1993; 148 650 655 (Pubitemid 23263774)
116. World Health Organization Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2006
117. Schoeman JF, Van Zyl LE, Laubscher JA et al. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics: 1997; 99 226 231 (Pubitemid 27148875)
118. Magdorf K, Detjen AK. Proposed management of childhood tuberculosis in low-incidence countries. Eur J Pediatr: 2008; 167 927 938
119. Abdool KSS, Naidoo K, Grobler A et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med: 2010; 362 697 706
120. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. rev.: 2010
121. Khan FA, Minion J, Pai M et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis: 2010; 50 1288 1299
122. Mofenson LM, Brady MT, Danner SP et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep: 2009; 58 11 1 166
123. Meintjes G, Wilkinson RJ, Morroni C et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS: 2010; 24 2381 2390
124. Milburn H, Ashman N, Davies P et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax: 2010; 65 557 570
125. Ellard G. Chemotherapy of tuberculosis for patients with renal impairment. Nephron: 1993; 64 169 181 (Pubitemid 23153042)
126. Milburn HJ. How should we treat tuberculosis in adult patients with chronic kidney disease? Key messages from the British Thoracic Society Guidelines. Pol Arch Med Wewn: 2010; 120 417 422
127. Pantel AM, McKeon J. Avoidance and management of adverse reactions to antituberculosis drugs. Drug Safety: 1995; 12 1 25
128. Holty JE, Sista RR. Mycobacterium tuberculosis infection in transplant recipients: early diagnosis and treatment of resistant tuberculosis. Curr Opin Organ Transplant: 2009; 14 613 618
129. Abdulgany-Hamadeh M. Tuberculosis and pregnancy. Chest: 1992; 101 1114 1120
130. Snider DE, Layde PM, Johnson MW et al. Treatment of tuberculosis during pregnancy. Am Rev Repir Dis: 1980; 122 65 79 (Pubitemid 10073544)
131. Raju B, Schluger NW. Tuberculosis and pregnancy. Sem Respir Crit Care Med: 1998; 19 298 305
132. Nhan-Chang CL, Jones TB. Tuberculosis in pregnancy. Clin Obstet Gynecol: 2010; 53 311 321
133. Mnyani CN, McIntyre JA. Tuberculosis in pregnancy. BJOG: 2011; 118 226 231
134. Snider DE, Powell KE. Should woman taking antituberculous drugs breast-feed? Arch Intern Med: 1984; 144 589 590 (Pubitemid 14152744)
135. Davies POD. Tuberculosis in the elderly. J Antimicrobiol Chemother: 1994; 34 A93 A100
136. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J: 1996; 9 2026 2030 (Pubitemid 26333539)
137. Diel R, Hauer B, Loddenkemper R et al. Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Pneumologie: 2009; 63 329 334
138. Solovic I, Sester M, Gomez-Reino JJ et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J: 2010; 36 1185 1206
139. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis: 2009; 48 1429 1432
140. Thompson NP, Caplin ME, Hamilton MI et al. Anti-tuberculous medication and the liver: dangers and recommendations in management. Eur Respir J: 1995; 8 1384 1388
141. Joint Committee of the British Thoracic Society Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax: 1998; 53 536 548
142. Kopanoff D, Snider DE, Caras GJ. Isoniazid-related hepatitis: a U. S. Public Health Service cooperative surveillance study. Am Rev Respir Dis: 1979; 117 991 1001
143. Centers for Disease Control and Prevention, ATS Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection. MMWR: 2003; 52 735 739
144. Matz J, Borish LC, Routes JM et al. Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med: 1994; 149 815 817 (Pubitemid 24082247)
145. Kobashi Y, Abe T, Shigeto E et al. Desensitization therapy for allergic reactions to antituberculous drugs. Intern Med: 2010; 49 2297 2301
146. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis: 1983; 5 S440 S450
147. Bruguerolle B. Chronopharmacokinetics. Current status. Clin Pharmacokinet: 1998; 35 83 94
148. Edwards OM, Courtney-Evans RJ, Galley JM et al. Changes in cortisol metabolism following rifampicin therapy. Lancet: 1974
149. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res: 1970; 20 1 63
150. American Thoracic Society, Centers for Disease Control Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med: 2000; 161 221 247
151. Smieja MJ, Marchetti CA, Cook DJ et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev: 2000; 02 CD001363
152. Akolo C, Adetifa I, Shepperd S et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev: 2010; 01 CD000171
153. Egsmose T, Ang'awa JO, Poti SJ. The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull World Health Organ: 1965; 33 419 433
154. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis: 1962; 85 490 510
155. International Union Against Tuberculosis Committee on Prophylaxis Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ: 1982; 60 555 564
156. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum: 2005; 52 1766 1772 (Pubitemid 40852885)
157. Horwitz O, Payne PG, Wilbek E. Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland. Bull World Health Organ: 1966; 35 509 526
158. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis: 1967; 95 935 943
159. Comstock GW, Baum C, Snider DE. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis: 1979; 119 827 830
160. Johnson JL, Okwera A, Hom D et al. Duration of treatment of latent tuberculosis infection in HIV-infected adults. AIDS: 2001; 15 2137 2147 (Pubitemid 33101821)
161. Elzi L, Schlegel M, Weber R et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis: 2007; 44 94 102 (Pubitemid 44968992)
162. International Union Against Tuberculosis and Lung Disease Interventions for tuberculosis control and elimination. Paris: 2002
163. Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis: 2009; 49 1883 1889
164. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis: 2005; 40 670 676 (Pubitemid 40381339)
165. Aspler A, Long R, Trajman A et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax: 2010; 65 582 587
166. Menzies D, Long R, Trajman A et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med: 2008; 149 689 697
167. Marais BJ, Hesseling AC, Gie RP et al. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis: 2006; 10 13 18 (Pubitemid 43266271)
168. Martinson NA, Barnes GL, Moulton LH et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med: 2011; 365 11 20
169. Stevens JP, Daniel TM. Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis. Chest: 1995; 108 712 717
170. Villarino ME, Dooley SW, Geiter LJ et al. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep: 1992; 41 61 71
171. Curry International Tuberculosis Center and California Department of Public Health Drug-resistant tuberculosis: A survival guide for clinicians. 2nd ed. San Francisco: 2011
172. Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med: 1969; 71 1113 1120
173. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med: 1999; 340 367 373
174. Diel R, Forssbohm M, Loytved G et al. Recommendations for background studies in tuberculosis. Pneumologie: 2007; 61 440 455
175. Chiang CY, van Deun A, Trebucq A et al. Treatment of multidrug-resistant tuberculosis: definition of the outcome failure'. Int J Tuberc Lung Dis: 2011; 15 4 5
176. Ewig S, Schaberg T, Rüsch-Gerdes S et al. Tuberkulose und
177. Aquinas M. Experiences with rifampicin. Bull Int Union Tuberc: 1974; 49 272 275
178. Aquinas M, Allan WG, Horsfall PA et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J: 1972; 1 765 771
179. Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg: 1973; 60 646 649
180. Hasenbosch RE, Alffenaar JW, Koopmans SA et al. Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. Int J Tuberc Lung Dis: 2008; 12 967 971
181. Russo PA, Chaglasian MA. Toxic optic neuropathy associated with ethambutol: implications for current therapy. J Am Optom Assoc: 1994; 65 332 338
182. Peloquin CA, Berning SE, Nitta AT et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis: 2004; 38 1538 1544 (Pubitemid 38738547)
183. Jugheli L, Bzekalava N, de Rijk P et al. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother: 2009; 53 5064 5068
184. Migliori GB, Eker B, Richardson MD et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J: 2009; 34 387 393
185. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med: 2009; 360 2397 2405